Selected article for: "anti inflammatory activity and inhibitory effect"
Author: Bahadoram, Mohammad; Keikhaei, Bijan; Saeedi-Boroujeni, Ali; Mahmoudian-Sani, Mohammad-Reza
Title: Chloroquine/hydroxychloroquine: an inflammasome inhibitor in severe COVID-19?
  • Cord-id: ldzqxv5u
  • Document date: 2021_1_8
    • ID: ldzqxv5u
    Snippet: Chloroquine and hydroxychloroquine belong to the aminoquinoline drugs. Studies revealed that chloroquine and hydroxychloroquine shows antagonism activity against COVID-19 under laboratory conditions. ARDS and ALI are conditions that occur in patients with COVID-19 as the main pathological complications of cytokine storm. Inflammasomes play a key role in the pathogenesis of many diseases associated with destructive inflammation. NLRP3 inflammasome has been shown to play a key role in the pathogen
    Document: Chloroquine and hydroxychloroquine belong to the aminoquinoline drugs. Studies revealed that chloroquine and hydroxychloroquine shows antagonism activity against COVID-19 under laboratory conditions. ARDS and ALI are conditions that occur in patients with COVID-19 as the main pathological complications of cytokine storm. Inflammasomes play a key role in the pathogenesis of many diseases associated with destructive inflammation. NLRP3 inflammasome has been shown to play a key role in the pathogenesis of viral diseases. The possible role of NLRP3 inflammasome inhibitors in the treatment of COVID-19 has been considered. We surveyed the potential inhibitory effect of chloroquine and hydroxychloroquine on inflammasome. Studies indicate that one of the possible anti-inflammatory mechanisms of chloroquine and hydroxychloroquine is inhibition of the activity of NLRP3 inflammasome.

    Search related documents:
    Co phrase search for related documents
    • acute ali lung injury and lopinavir ritonavir: 1
    • acute ali lung injury and low respiratory: 1, 2
    • acute ali lung injury and low respiratory tract: 1
    • acute ali lung injury and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute ali lung injury and lung tissue: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute ards respiratory distress syndrome and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute ards respiratory distress syndrome and lopinavir ritonavir effectiveness: 1
    • acute ards respiratory distress syndrome and low respiratory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute ards respiratory distress syndrome and low respiratory tract: 1, 2
    • acute ards respiratory distress syndrome and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute ards respiratory distress syndrome and lung tissue: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • lopinavir ritonavir and low respiratory: 1, 2
    • lopinavir ritonavir and low respiratory tract: 1
    • lopinavir ritonavir and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • lopinavir ritonavir and lung tissue: 1, 2, 3, 4, 5, 6, 7, 8
    • lopinavir ritonavir and lupus rheumatic disease: 1
    • lopinavir ritonavir and lupus rheumatic disease rheumatoid arthritis: 1
    • lopinavir ritonavir protease inhibitor and lung injury: 1
    • low respiratory and lung tissue: 1, 2, 3, 4, 5, 6, 7